UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Combinatorial Regulation of Neuroblastoma Tumor Progression by N-Myc and Hypoxia Inducible Factor HIF-1α

Cancer research (Chicago, Ill.), 2010-12, Vol.70 (24), p.10351-10361

2010

Volltextzugriff (PDF)

Intratumoral De Novo Steroid Synthesis Activates Androgen Receptor in Castration-Resistant Prostate Cancer and Is Upregulated by Treatment with CYP17A1 Inhibitors

Cancer research (Chicago, Ill.), 2011-10, Vol.71 (20), p.6503-6513

2011

Volltextzugriff (PDF)

Targeting Activin Receptor-Like Kinase 1 Inhibits Angiogenesis and Tumorigenesis through a Mechanism of Action Complementary to Anti-VEGF Therapies

Cancer research (Chicago, Ill.), 2011-02, Vol.71 (4), p.1362-1373

2011

Volltextzugriff (PDF)

Gene expression profiling reveals a massive, aneuploidy-dependent transcriptional deregulation and distinct differences between lymph node-negative and lymph node-positive colon carcinomas

Cancer research (Chicago, Ill.), 2007, Vol.67 (1), p.41-56

2007

Volltextzugriff (PDF)

GF-15, a Novel Inhibitor of Centrosomal Clustering, Suppresses Tumor Cell Growth In Vitro and In Vivo

Cancer research (Chicago, Ill.), 2012-10, Vol.72 (20), p.5374-5385

2012

Volltextzugriff (PDF)

Quantitative Phosphoproteomics Reveals a Cluster of Tyrosine Kinases That Mediates Src invasive Activity in Advanced Colon Carcinoma Cells

Cancer research (Chicago, Ill.), 2009-03, Vol.69 (6), p.2279-2286

2009

Volltextzugriff (PDF)

Abstract GS2-02: Elacestrant, an oral selective estrogen receptor degrader (SERD), vs investigator’s choice of endocrine monotherapy for ER+/HER2- advanced/metastatic breast cancer (mBC) following progression on prior endocrine and CDK4/6 inhibitor therapy: Results of EMERALD phase 3 trial

Cancer research (Chicago, Ill.), 2022-02, Vol.82 (4_Supplement), p.GS2-02-GS2-02

2022

Volltextzugriff (PDF)

Abstract 4750: The role of drug transporters in the acquired resistance to PBD dimer-containing antibody drug conjugates

Cancer research (Chicago, Ill.), 2019-07, Vol.79 (13_Supplement), p.4750-4750

2019

Volltextzugriff (PDF)

Abstract 234: Pre-clinical characterization of 3A4-PL1601, a novel pyrrolobenzodiazepine (PBD) dimer-based antibody-drug conjugate (ADC) directed against KAAG1-expressing malignancies

Cancer research (Chicago, Ill.), 2019-07, Vol.79 (13_Supplement), p.234-234

2019

Volltextzugriff (PDF)

Abstract OT2-11-03: AMEERA-1 : Phase 1/2 study of amcenestrant (SAR439859), an oral selective estrogen receptor (ER) degrader (SERD), with alpelisib in postmenopausal women with ER+/human epidermal growth factor receptor 2-negative (HER2-) PIK3CA -mutated advanced breast cancer

Cancer research (Chicago, Ill.), 2022-02, Vol.82 (4_Supplement), p.OT2-11-03-OT2-11-03

2022

Volltextzugriff (PDF)

Abstract LB-016: Nutlin and oxaliplatin induce p53-dependent addiction to FLIP

Cancer research (Chicago, Ill.), 2016-07, Vol.76 (14_Supplement), p.LB-016-LB-016

2016

Volltextzugriff (PDF)

Loss-of-Function Variants in the Tumor-Suppressor Gene PTPN14 Confer Increased Cancer Risk

Cancer research (Chicago, Ill.), 2021-04, Vol.81 (8), p.1954-1964

2021

Volltextzugriff (PDF)

Abstract LB-034: Development and characterization of PDX-derived 3D tumor microtissues as platform for screening targeted molecular therapeutics

Cancer research (Chicago, Ill.), 2018-07, Vol.78 (13_Supplement), p.LB-034-LB-034

2018

Volltextzugriff (PDF)

Abstract 51: Characterization of the mechanism of action, pharmacodynamics and preclinical safety of ADCT-402, a pyrrolobenzodiazepine (PBD) dimer-containing antibody-drug conjugate (ADC) targeting CD19-expressing hematological malignancies

Cancer research (Chicago, Ill.), 2017-07, Vol.77 (13_Supplement), p.51-51

2017

Volltextzugriff (PDF)

Abstract P5-16-08: Phase Ib/II trial evaluating safety and efficacy of copanlisib (PI3K inhibitor) and trastuzumab in pre-treated advanced HER2-positive breast cancer: Results from the PantHER study

Cancer research (Chicago, Ill.), 2022-02, Vol.82 (4_Supplement), p.P5-P5-16-08

2022

Volltextzugriff (PDF)

Abstract GS3-10: Study of samuraciclib (CT7001), a first-in-class, oral, selective inhibitor of CDK7, in combination with fulvestrant in patients with advanced hormone receptor positive HER2 negative breast cancer (HR+BC)

Cancer research (Chicago, Ill.), 2022-02, Vol.82 (4_Supplement), p.GS3-10-GS3-10

2022

Volltextzugriff (PDF)

Abstract 3111A: ADCT-401/MEDI3726, a novel pyrrolobenzodiazepine (PBD)-based antibody-drug conjugate (ADC) targeting PSMA-expressing prostate cancers

Cancer research (Chicago, Ill.), 2017-07, Vol.77 (13_Supplement), p.3111-3111A

2017

Volltextzugriff (PDF)

The ΔNp63 Proteins Are Key Allies of BRCA1 in the Prevention of Basal-Like Breast Cancer

Cancer research (Chicago, Ill.), 2011-03, Vol.71 (5), p.1933-1944

2011

Volltextzugriff (PDF)

Abstract A004: MEDI3726 (ADCT-401), a novel antibody-drug conjugate targeting PSMA, has potent in vivo antitumor activity in prostate cancer patient-derived xenograft models

Cancer research (Chicago, Ill.), 2018-08, Vol.78 (16_Supplement), p.A004-A004

2018

Volltextzugriff (PDF)

Abstract 1046: Prevalence of MTAP deficiencyin human cancer: A tissue microarray study on 17,078 cancers from 149 different tumor types

Cancer research (Chicago, Ill.), 2024-03, Vol.84 (6_Supplement), p.1046-1046

2024

Volltextzugriff (PDF)

Abstract PO5-01-02: A retrospective review of pathological complete response and toxicity rates to a modified version of TCHP (Paclitaxel, Trastuzumab, Pertuzumab, Carboplatin) for HER2 positive breast cancer stage II and III

Cancer research (Chicago, Ill.), 2024-05, Vol.84 (9_Supplement), p.PO5-01-02-PO5-01-02

2024

Volltextzugriff (PDF)

Abstract LB037: 89ZED88082A PET imaging to visualize CD8+ T cells in patients with cancer treated with immune checkpoint inhibitor

Cancer research (Chicago, Ill.), 2021-07, Vol.81 (13_Supplement), p.LB037-LB037

2021

Volltextzugriff (PDF)

Abstract 2409: FLIP(L) determines colon cancer cell fate following p53 activation

Cancer research (Chicago, Ill.), 2020-08, Vol.80 (16_Supplement), p.2409-2409

2020

Volltextzugriff (PDF)

Abstract P1-19-24: A phase Ib trial of copanlisib in combination with trastuzumab in pretreated recurrent or metastatic HER2-positive breast cancer “PantHER”

Cancer research (Chicago, Ill.), 2020-02, Vol.80 (4_Supplement), p.P1-P1-19-24

2020

Volltextzugriff (PDF)

Abstract P2-19-01: Impact of bone-only metastatic breast cancer on outcome in a real-life setting: A comprehensive analysis of 5,041 women from the ESME database

Cancer research (Chicago, Ill.), 2020-02, Vol.80 (4_Supplement), p.P2-P2-19-01

2020

Volltextzugriff (PDF)

1 – 25 von 64

Suche als RSS-Feed

Aktive Filter

ThemaScience & Technology - Other Topics

Zeitschrift / SerieCancer Research

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(64)
Mit Volltextzugriff
(60)

Publikationsform

Artikel
(64)

Sprache

Englisch
(64)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

Menü

Weitere Dienste

Einstellungen

Combinatorial Regulation of Neuroblastoma Tumor Progression by N-Myc and Hypoxia Inducible Factor HIF-1α

Intratumoral De Novo Steroid Synthesis Activates Androgen Receptor in Castration-Resistant Prostate Cancer and Is Upregulated by Treatment with CYP17A1 Inhibitors

Targeting Activin Receptor-Like Kinase 1 Inhibits Angiogenesis and Tumorigenesis through a Mechanism of Action Complementary to Anti-VEGF Therapies

Gene expression profiling reveals a massive, aneuploidy-dependent transcriptional deregulation and distinct differences between lymph node-negative and lymph node-positive colon carcinomas

GF-15, a Novel Inhibitor of Centrosomal Clustering, Suppresses Tumor Cell Growth In Vitro and In Vivo

Quantitative Phosphoproteomics Reveals a Cluster of Tyrosine Kinases That Mediates Src invasive Activity in Advanced Colon Carcinoma Cells

Abstract GS2-02: Elacestrant, an oral selective estrogen receptor degrader (SERD), vs investigator’s choice of endocrine monotherapy for ER+/HER2- advanced/metastatic breast cancer (mBC) following progression on prior endocrine and CDK4/6 inhibitor therapy: Results of EMERALD phase 3 trial

Abstract 4750: The role of drug transporters in the acquired resistance to PBD dimer-containing antibody drug conjugates

Abstract 234: Pre-clinical characterization of 3A4-PL1601, a novel pyrrolobenzodiazepine (PBD) dimer-based antibody-drug conjugate (ADC) directed against KAAG1-expressing malignancies

Abstract OT2-11-03: AMEERA-1 : Phase 1/2 study of amcenestrant (SAR439859), an oral selective estrogen receptor (ER) degrader (SERD), with alpelisib in postmenopausal women with ER+/human epidermal growth factor receptor 2-negative (HER2-) PIK3CA -mutated advanced breast cancer

Abstract LB-016: Nutlin and oxaliplatin induce p53-dependent addiction to FLIP

Loss-of-Function Variants in the Tumor-Suppressor Gene PTPN14 Confer Increased Cancer Risk

Abstract LB-034: Development and characterization of PDX-derived 3D tumor microtissues as platform for screening targeted molecular therapeutics

Abstract 51: Characterization of the mechanism of action, pharmacodynamics and preclinical safety of ADCT-402, a pyrrolobenzodiazepine (PBD) dimer-containing antibody-drug conjugate (ADC) targeting CD19-expressing hematological malignancies

Abstract P5-16-08: Phase Ib/II trial evaluating safety and efficacy of copanlisib (PI3K inhibitor) and trastuzumab in pre-treated advanced HER2-positive breast cancer: Results from the PantHER study

Abstract GS3-10: Study of samuraciclib (CT7001), a first-in-class, oral, selective inhibitor of CDK7, in combination with fulvestrant in patients with advanced hormone receptor positive HER2 negative breast cancer (HR+BC)

Abstract 3111A: ADCT-401/MEDI3726, a novel pyrrolobenzodiazepine (PBD)-based antibody-drug conjugate (ADC) targeting PSMA-expressing prostate cancers

The ΔNp63 Proteins Are Key Allies of BRCA1 in the Prevention of Basal-Like Breast Cancer

Abstract A004: MEDI3726 (ADCT-401), a novel antibody-drug conjugate targeting PSMA, has potent in vivo antitumor activity in prostate cancer patient-derived xenograft models

Abstract 1046: Prevalence of MTAP deficiencyin human cancer: A tissue microarray study on 17,078 cancers from 149 different tumor types

Abstract PO5-01-02: A retrospective review of pathological complete response and toxicity rates to a modified version of TCHP (Paclitaxel, Trastuzumab, Pertuzumab, Carboplatin) for HER2 positive breast cancer stage II and III

Abstract LB037: 89ZED88082A PET imaging to visualize CD8+ T cells in patients with cancer treated with immune checkpoint inhibitor

Abstract 2409: FLIP(L) determines colon cancer cell fate following p53 activation

Abstract P1-19-24: A phase Ib trial of copanlisib in combination with trastuzumab in pretreated recurrent or metastatic HER2-positive breast cancer “PantHER”

Abstract P2-19-01: Impact of bone-only metastatic breast cancer on outcome in a real-life setting: A comprehensive analysis of 5,041 women from the ESME database

Aktive Filter

Suchergebnisse filtern